Providing sustained, around the clock control of your patients’ K+, and proven to allow guideline-recommended RAASi therapy. Veltassa® is reliable and easy to use with no sodium-associated risk.1–7


What is Veltassa®?

Veltassa® (patiromer sorbitex calcium) is a novel, next-generation, non-absorbed cation exchange polymer indicated for the treatment of hyperkalemia in adults.6,7

Veltassa® has been designed specifically to exchange K+ for Ca2+ rather than Na+.7

Veltassa® increases faecal K+ excretion by exchanging Ca2+ for K+ in the lumen of the GI tract and reducing serum levels of this cation7,8

Read more

Ca2 ions released during the ion-exchange process may be absorbed, rebind to Veltassa®, remain in solution, or bind to anions, such as phosphate, to form relatively insoluble salt complexes


Veltassa® has been designed to be fully ionised at the physiological pH of the colon, where the concentration of K+ in the GI tract is highest,6,9 for optimal ion exchange

Veltassa® has a 1.5–2-fold higher K+ binding capacity than other polymers6

Veltassa® is not absorbed and remains physically intact during its passage through the GI tract7


Veltassa® Mode of Action

Veltassa® is manufactured using a suspension polymerisation process that results in insoluble spherical beads of uniform and controlled size.

Veltassa®’s smooth microbead structure and low swelling ratio may minimise undesirable GI effects and lead to improved tolerability for patients.6


Veltassa® is the once daily solution for long-term K+ control


Mix 3 tablespoons of water or alternative liquid/soft food with an entire sachet of Veltassa®, then stir7


Add another 3 tablespoons of water or alternative liquid/soft food and stir thoroughly. The powder will not dissolve and the mixture will look cloudy7


Drink immediately. If powder remains in the glass after consuming, repeat steps 2 and 3 to ensure the entire dose is taken7


Favourable safety & tolerability

Veltassa® has demonstrated a positive risk/benefit profile in hyperkalemia management from both the clinical trial programme and real-world practice.

ADRs in clinical studies
System Organ Class Common Uncommon
Metabolism and nutrition disorders
Gastrointestinal disorders
Abdominal pain:2.9%
  • No dose-related oedema observed in over 52 weeks of treatment2
  • Hypokalemia was not identified as an ADR2
  • The majority of the ADRs reported from trials were gastrointestinal disorders and hypomagnesemia7
  • GI ADRs were generally mild-to-moderate in nature and did not appear to be dose-related. They generally resolved spontaneously or with treatment, and none were reported as serious7
  • No patients developed magnesium levels <1 mg/dL.7 Serum magnesium should be monitored for at least 1 month after initiating treatment, and magnesium supplementation considered in patients who develop low serum magnesium levels7

The favourable safety profile observed in clinical trials is supported by evidence from real-world studies.

In real-world practice, an estimated >400,000 patients have been exposed to Veltassa®.12


No sodium risk

Excess Na+ intake is associated with increased CV and renal risks:2–12

Increased blood pressure13-15

Decreased reno-protective benefits of RAASi medication16-18

CV morbidity and mortality13,19-22

Increased albuminuria15,23

Veltassa® is suitable for sodium-sensitive patients

The use of Ca2+ rather than Na+ may make Veltassa® a good choice for hyperkalemia management in patients who cannot tolerate even small increases in Na+, such as patients with HF, CKD, severe hypertension or marked oedema6